Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Consumer OTC Drugs

Pfizer Consumer Business Not Critical During “Transition” Year

This article was originally published in The Tan Sheet

  • News
  • The Tan Sheet

Executive Summary

Pfizer does not consider its consumer business to be key to the company's strategic outlook during the 2005 "transition" year, CEO Hank McKinnell indicated during an April 5 business review with analysts

You may also be interested in...



Pfizer Eyes Consumer Unit Spin-Off Or Sale Price North of $10 Bil.

Pfizer has "no interest" in separately divesting individual products from its consumer division, CEO Hank McKinnell said during a Feb. 10 analysts presentation

Pfizer Eyes Consumer Unit Spin-Off Or Sale Price North of $10 Bil.

Pfizer has "no interest" in separately divesting individual products from its consumer division, CEO Hank McKinnell said during a Feb. 10 analysts presentation

Pfizer Eyes Consumer Unit Spin-Off Or Sale Price North of $10 Bil.

Pfizer has "no interest" in separately divesting individual products from its consumer division, CEO Hank McKinnell said during a Feb. 10 analysts presentation

Table

View full table

Related Content

HBW Insight
Pink Sheet

Topics

Tags:
Consumer OTC Drugs
Latest Headlines

Global Pharma Guidance Tracker – March 2024

EU Stakeholders Devise Six-Point Plan To Improve Cross-Border Clinical Trials

Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings

China’s Public Payer Wants To Define Innovative Drugs As Those With ‘Novel Benefits’

See All
UsernamePublicRestriction

Register

PS098070

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By